BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21626498)

  • 1. [Nephrotoxicity induced by chemotherapy].
    Di Vito R; Sirolli V; Amoroso L; Bonomini M
    G Ital Nefrol; 2011; 28(3):296-304. PubMed ID: 21626498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention and management of nephrotoxicity from anti-cancer agents].
    Miyazaki J; Kawai K
    Nihon Rinsho; 2003 Jun; 61(6):973-7. PubMed ID: 12806945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversity in renal function monitoring and dose modifications during treatment for childhood cancer: a call for standardization.
    Blufpand HN; Hes N; Bökenkamp A; van de Wetering MD; Kaspers GJ
    Pediatr Blood Cancer; 2014 Feb; 61(2):337-44. PubMed ID: 23907811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hematological malignancies in patients affected by renal failure.
    Niscola P; Vischini G; Tendas A; Scaramucci L; Giovannini M; Bondanini F; Romani C; Brunetti GA; Cartoni C; Cupelli L; Ferrannini M; Perrotti A; Del Poeta G; Palumbo R; de Fabritiis P
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):415-32. PubMed ID: 21417855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal toxicities of chemotherapy.
    de Jonge MJ; Verweij J
    Semin Oncol; 2006 Feb; 33(1):68-73. PubMed ID: 16473645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.
    Launay-Vacher V; Oudard S; Janus N; Gligorov J; Pourrat X; Rixe O; Morere JF; Beuzeboc P; Deray G;
    Cancer; 2007 Sep; 110(6):1376-84. PubMed ID: 17634949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of monitoring renal function in patients with cancer.
    Aapro M; Launay-Vacher V
    Cancer Treat Rev; 2012 May; 38(3):235-40. PubMed ID: 21605937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of renal function in the patient receiving chemotherapy.
    Lydon J
    Cancer Nurs; 1989 Jun; 12(3):133-43. PubMed ID: 2743296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity--what do we know and what don't we know?
    Skinner R
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):128-34. PubMed ID: 21285904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
    Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal disease in patients with cancer.
    Finkel KW; Foringer JR
    Nat Clin Pract Nephrol; 2007 Dec; 3(12):669-78. PubMed ID: 18033226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal complications of anti-cancer chemotherapy].
    Fillastre JP; Moulin B; Godin M; Josse S
    Pathol Biol (Paris); 1986 Nov; 34(9):1013-28. PubMed ID: 3543812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of common drugs used by urologists.
    Bennett WM; Porter GA
    Urol Clin North Am; 1990 Feb; 17(1):145-56. PubMed ID: 2407013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
    Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
    Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nephrotoxicity of cytostatic drugs. Pathogenesis, prevention, therapy].
    Tesar V; Tesarová P; Klener P
    Cas Lek Cesk; 1997 Apr; 136(7):205-9. PubMed ID: 9221195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onco-nephrology: renal toxicities of chemotherapeutic agents.
    Perazella MA
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1713-21. PubMed ID: 22879440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
    Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater risks of chemotherapy toxicity in elderly patients with cancer.
    Repetto L
    J Support Oncol; 2003; 1(4 Suppl 2):18-24. PubMed ID: 15346996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
    Lyubimova NV; Topchieva SV; Averinova SG; Kashkadaeva AV; Gorbunova VA; Shiryaev SV; Kushlinskii NE
    Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention and treatment of the side effects of cancer chemotherapy].
    Iki S; Urabe A
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1635-40. PubMed ID: 11057312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.